- €13.07bn
- €12.06bn
- €3.93bn
Brief: Ipsen Late-Breaking Data Raises Ambitions In PBC
Brief: Charles River Laboratories International Virtual Control Group To Be Used In Glp Study For Ipsen
Pharming shares rise after preliminary Q3 revenue beat
France's Ipsen Q3 sales rise 28% driven by core portfolio
Brief: Ipsen Q3 Total Sales €1,173.9 Million
RCS - Accession Theraptcs. - Accession Therapeutics: Board appointments
Europe Research Roundup: Barratt Redrow, Man Group, Sika
US FDA approves Mirum's drug for rare bone disorder (updated)
US FDA approves Mirum's drug for rare bone disorder
European drugmakers call for faster trials, more spending to compete with US, China
Ipsen falls after US FDA approves generic Somatuline
Brief: Ipsen Appoints Mariette Finet To Its Board Of Directors
Top of the Street: Kion, Hikma Pharmaceuticals, Ipsen, Auto Trader, Randstad, Saab
Barclays stays neutral on European pharma for 2027
Brief: Ipsen Completes Acquisition Of Kartos Therapeutics
Europe Research Roundup: Bawag Group, Natwest Group, Mersen
Jefferies cuts Ipsen to 'underperform' on Somatuline competition risk
France's Ipsen H1 revenue rises 20.4%, lifts 2026 outlook
Brief: Ipsen: Phase III Bold Trial Of Bylvay In Biliary Atresia Doesn't Meet Primary Endpoint